Yet another project focusing on antibody-drug conjugates (ADC) is to get underway, following an agreement between German firm Tubulis and Bristol Myers Squibb (NYSE: BMY).
The deal gives Bristol Myers exclusive rights to access Tubulis’ Tubutecan payloads and proprietary P5 conjugation platform.
The New York-based cancer giant has agreed to pay up to around a billion dollars in development, regulatory and commercial milestones.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze